NHS drugs go-ahead offers lifeline to children with rare muscle-wasting disease

The National Institute for Health and Care Excellence has approved two treatments for spinal muscular atrophy, a rare muscle-wasting disease. This decision will provide a lifeline to hundreds of children with the condition, improving their survival rates. The move has been hailed as a significant breakthrough by parents of affected children.